国信证券：创新出海2.0成果卓著 对外授权成创新药公司重要收入来源

Group 1 - The pharmaceutical sector has shown outstanding stock performance in the first half of the year, driven by continuous BD overseas expansion, excellent clinical data, and policy support, with the innovative drug sector leading the way [1] - The domestic market is experiencing rapid sales growth as a series of significant products are approved and included in medical insurance, with external licensing income becoming an important revenue source for innovative drug companies [1] - Chinese innovative drugs are increasingly gaining importance in the global market, with a rapid increase in the number and value of licensing transactions, expanding from oncology to autoimmune and metabolic disease areas [2] Group 2 - The payment side of the domestic market is continuously optimizing, with recent medical insurance negotiations resulting in a milder price reduction trend, allowing most innovative drugs to achieve rapid sales growth through price-volume trade-offs [3] - New heavy-weight products are expected to quickly realize their commercial value domestically, supported by local policies for innovative drugs [3] - The addition of a commercial insurance innovative drug directory in this year's catalog adjustment is expected to provide new growth opportunities for innovative drugs [3]